美FDA全面批准16歲或以上人士使用「復必泰」新冠疫苗
美國食品及藥物管理局(FDA)正式全面批准使用輝瑞(Pfizer)(PFE.US)及BioNTech研發的「復必泰」新冠疫苖,為當局首次全面批准使用新冠疫苗。
當局去年12月批准「復必泰」緊急使用,現基於公司提交的最新數據,涉及臨床測試及生產檢視,全面批准「復必泰」於16歲或以上人士使用。衛生官員希望有關批准能說服未接種疫苗美國民眾,有關疫苗安全有效,又預期將有更多州及地區政府,以至私營機構僱主實施強制接種要求。
美國總統拜登回應時指出,有關批准為美國政府對抗新冠疫情的重要時刻,促請更多私營機構規定員工接種疫苗。美國國防部已表示,預備強制所有士兵接種。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.